dc.contributor.author | Nikolopoulos, Georgios K. | en |
dc.contributor.author | Paraskeva, D. | en |
dc.contributor.author | Psichogiou, M. | en |
dc.contributor.author | Hatzakis, A. | en |
dc.creator | Nikolopoulos, Georgios K. | en |
dc.creator | Paraskeva, D. | en |
dc.creator | Psichogiou, M. | en |
dc.creator | Hatzakis, A. | en |
dc.date.accessioned | 2018-06-22T09:54:07Z | |
dc.date.available | 2018-06-22T09:54:07Z | |
dc.date.issued | 2016 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42199 | |
dc.description.abstract | The coinfection of Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) has been associated with increased death rates. However, the relevant research has mostly relied on serologic HBV testing [HBV surface antigen (HBsAg)]. The aim of this work was to explore the relationship of HBV viraemia with overall mortality among HIV/HBV coinfected individuals. The analysis included 1,609 HIV seropositives of a previously described cohort (1984-2003) with limited exposure to tenofovir (12%) and a median follow-up of approximately 5 years. Those with persistent expression of HBsAg were further tested for HBV-DNA. The data were analyzed using Poisson regression models. Totally, 101 participants were chronic carriers of HBsAg (6.28%). Of these, 81 were tested for HBV-DNA. The median HBV-DNA levels were 3.81 log (base-10) International Units (IU)/ml. A third (31%) of those tested for HBV-DNA had received tenofovir. Before developing acquired immune deficiency syndrome (AIDS), the adjusted incidence rate ratio (IRR) for all-cause mortality of coinfected patients with HBV viraemia above the median value versus the HIV monoinfected group was 3.44 [95% confidence interval (CI): 1.05-11.27]. Multivariable regressions in the coinfected group only (n=81) showed that one log-10 increase in HBV-DNA levels was associated with an elevated risk for death (IRR: 1.24, 95%CI: 1.03-1.49). HBV-DNA levels predict overall mortality in the setting of HIV/HBV coinfection, especially during the period before developing AIDS, and could thus help prioritize needs and determine the frequency of medical monitoring. © 2016 Wiley Periodicals, Inc. | en |
dc.language.iso | eng | en |
dc.source | Journal of medical virology | en |
dc.subject | Human | en |
dc.subject | Humans | en |
dc.subject | Controlled study | en |
dc.subject | Female | en |
dc.subject | Major clinical study | en |
dc.subject | Follow up | en |
dc.subject | Prediction | en |
dc.subject | Mortality | en |
dc.subject | Adolescent | en |
dc.subject | Human immunodeficiency virus infection | en |
dc.subject | Lamivudine | en |
dc.subject | Male | en |
dc.subject | Incidence | en |
dc.subject | Follow-up studies | en |
dc.subject | Hiv infections | en |
dc.subject | Blood | en |
dc.subject | Prevalence | en |
dc.subject | Article | en |
dc.subject | Middle aged | en |
dc.subject | Cohort analysis | en |
dc.subject | Genetics | en |
dc.subject | Highly active antiretroviral therapy | en |
dc.subject | Viral | en |
dc.subject | Viremia | en |
dc.subject | Virus load | en |
dc.subject | Dna | en |
dc.subject | Virology | en |
dc.subject | Viral load | en |
dc.subject | Hiv | en |
dc.subject | Drug effects | en |
dc.subject | Human immunodeficiency virus 1 | en |
dc.subject | Hiv-1 | en |
dc.subject | Cd4 lymphocyte count | en |
dc.subject | Coinfection | en |
dc.subject | Hbv | en |
dc.subject | Hepatitis b | en |
dc.subject | Hepatitis b virus | en |
dc.subject | Mixed infection | en |
dc.subject | Acquired immune deficiency syndrome | en |
dc.subject | Hepatitis b surface antigen | en |
dc.subject | Tenofovir | en |
dc.subject | Poisson distribution | en |
dc.subject | Isolation and purification | en |
dc.subject | Hepatitis b surface antigens | en |
dc.subject | Hbv-dna | en |
dc.subject | Virus dna | en |
dc.title | HBV-DNA levels predict overall mortality in HIV/HBV coinfected individuals | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1002/jmv.24357 | |
dc.description.volume | 88 | |
dc.description.issue | 3 | |
dc.description.startingpage | 466 | |
dc.description.endingpage | 473 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Nikolopoulos, Georgios K.[0000-0002-3307-0246] | |
dc.contributor.orcid | Psichogiou, M. [0000-0002-3000-8447] | |
dc.gnosis.orcid | 0000-0002-3307-0246 | |
dc.gnosis.orcid | 0000-0002-3000-8447 | |